Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study

Amy Berrington De Gonzalez, Eun Yun Ji, Sang Yi Lee, Alison Klein, Ha Jee Sun

Research output: Contribution to journalArticle

Abstract

There is increasing evidence that type 2 diabetes mellitus and glucose intolerance are a cause, not just a consequence, of pancreatic cancer. We examined whether other factors that characterize the insulin resistance syndrome are also risk factors for pancreatic cancer in a prospective cohort study of 631,172 men and women (ages 45+ years) who received health insurance from the Korean Medical Insurance Corporation. The biennial medical evaluations from 1992 to 1995 provided the baseline information for this study. Relative risks (RR) were estimated using proportional hazards models adjusted for age, sex, smoking, and fasting serum glucose (after excluding the first 2 years of follow-up). There were 2,194 incident cases of pancreatic cancer diagnosed in the cohort over a median follow-up of 12 years. There was no evidence that pancreatic cancer risk was associated with total cholesterol, systolic blood pressure, WBC count, or body mass index. Abnormal levels of aspartate aminotransferase and alanine aminotransferase were both associated with a moderately increased risk of developing the disease (40+ versus trend = 0.05 and RR, 1.34; 95% CI, 1.16-1.56; Ptrend = 0.02, respectively). Excluding 6 years of follow-up reduced this RR (95% CI) for aspartate aminotransferase to 1.22 (1.01-1.49), but even after excluding 10 years follow-up the RR (95% CI) for alanine aminotransferase was unchanged [1.36 (1.01-1.83)]. Although fasting serum glucose has been found previously to be associated with pancreatic cancer risk in this cohort, most other factors that characterize insulin resistance syndrome were not associated with pancreatic cancer risk. The association with elevated liver enzyme levels is a novel finding that warrants further investigation.

Original languageEnglish (US)
Pages (from-to)359-364
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Pancreatic Neoplasms
Insulin Resistance
Neoplasms
Aspartate Aminotransferases
Alanine Transaminase
Fasting
Blood Pressure
Glucose
Glucose Intolerance
Health Insurance
Insurance
Serum
Proportional Hazards Models
Type 2 Diabetes Mellitus
Body Mass Index
Cohort Studies
Smoking
Cholesterol
Prospective Studies
Liver

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study. / De Gonzalez, Amy Berrington; Ji, Eun Yun; Lee, Sang Yi; Klein, Alison; Sun, Ha Jee.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 2, 01.02.2008, p. 359-364.

Research output: Contribution to journalArticle

@article{ea363da6f62c4275bb160ba96ecb478d,
title = "Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study",
abstract = "There is increasing evidence that type 2 diabetes mellitus and glucose intolerance are a cause, not just a consequence, of pancreatic cancer. We examined whether other factors that characterize the insulin resistance syndrome are also risk factors for pancreatic cancer in a prospective cohort study of 631,172 men and women (ages 45+ years) who received health insurance from the Korean Medical Insurance Corporation. The biennial medical evaluations from 1992 to 1995 provided the baseline information for this study. Relative risks (RR) were estimated using proportional hazards models adjusted for age, sex, smoking, and fasting serum glucose (after excluding the first 2 years of follow-up). There were 2,194 incident cases of pancreatic cancer diagnosed in the cohort over a median follow-up of 12 years. There was no evidence that pancreatic cancer risk was associated with total cholesterol, systolic blood pressure, WBC count, or body mass index. Abnormal levels of aspartate aminotransferase and alanine aminotransferase were both associated with a moderately increased risk of developing the disease (40+ versus trend = 0.05 and RR, 1.34; 95{\%} CI, 1.16-1.56; Ptrend = 0.02, respectively). Excluding 6 years of follow-up reduced this RR (95{\%} CI) for aspartate aminotransferase to 1.22 (1.01-1.49), but even after excluding 10 years follow-up the RR (95{\%} CI) for alanine aminotransferase was unchanged [1.36 (1.01-1.83)]. Although fasting serum glucose has been found previously to be associated with pancreatic cancer risk in this cohort, most other factors that characterize insulin resistance syndrome were not associated with pancreatic cancer risk. The association with elevated liver enzyme levels is a novel finding that warrants further investigation.",
author = "{De Gonzalez}, {Amy Berrington} and Ji, {Eun Yun} and Lee, {Sang Yi} and Alison Klein and Sun, {Ha Jee}",
year = "2008",
month = "2",
day = "1",
doi = "10.1158/1055-9965.EPI-07-0507",
language = "English (US)",
volume = "17",
pages = "359--364",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study

AU - De Gonzalez, Amy Berrington

AU - Ji, Eun Yun

AU - Lee, Sang Yi

AU - Klein, Alison

AU - Sun, Ha Jee

PY - 2008/2/1

Y1 - 2008/2/1

N2 - There is increasing evidence that type 2 diabetes mellitus and glucose intolerance are a cause, not just a consequence, of pancreatic cancer. We examined whether other factors that characterize the insulin resistance syndrome are also risk factors for pancreatic cancer in a prospective cohort study of 631,172 men and women (ages 45+ years) who received health insurance from the Korean Medical Insurance Corporation. The biennial medical evaluations from 1992 to 1995 provided the baseline information for this study. Relative risks (RR) were estimated using proportional hazards models adjusted for age, sex, smoking, and fasting serum glucose (after excluding the first 2 years of follow-up). There were 2,194 incident cases of pancreatic cancer diagnosed in the cohort over a median follow-up of 12 years. There was no evidence that pancreatic cancer risk was associated with total cholesterol, systolic blood pressure, WBC count, or body mass index. Abnormal levels of aspartate aminotransferase and alanine aminotransferase were both associated with a moderately increased risk of developing the disease (40+ versus trend = 0.05 and RR, 1.34; 95% CI, 1.16-1.56; Ptrend = 0.02, respectively). Excluding 6 years of follow-up reduced this RR (95% CI) for aspartate aminotransferase to 1.22 (1.01-1.49), but even after excluding 10 years follow-up the RR (95% CI) for alanine aminotransferase was unchanged [1.36 (1.01-1.83)]. Although fasting serum glucose has been found previously to be associated with pancreatic cancer risk in this cohort, most other factors that characterize insulin resistance syndrome were not associated with pancreatic cancer risk. The association with elevated liver enzyme levels is a novel finding that warrants further investigation.

AB - There is increasing evidence that type 2 diabetes mellitus and glucose intolerance are a cause, not just a consequence, of pancreatic cancer. We examined whether other factors that characterize the insulin resistance syndrome are also risk factors for pancreatic cancer in a prospective cohort study of 631,172 men and women (ages 45+ years) who received health insurance from the Korean Medical Insurance Corporation. The biennial medical evaluations from 1992 to 1995 provided the baseline information for this study. Relative risks (RR) were estimated using proportional hazards models adjusted for age, sex, smoking, and fasting serum glucose (after excluding the first 2 years of follow-up). There were 2,194 incident cases of pancreatic cancer diagnosed in the cohort over a median follow-up of 12 years. There was no evidence that pancreatic cancer risk was associated with total cholesterol, systolic blood pressure, WBC count, or body mass index. Abnormal levels of aspartate aminotransferase and alanine aminotransferase were both associated with a moderately increased risk of developing the disease (40+ versus trend = 0.05 and RR, 1.34; 95% CI, 1.16-1.56; Ptrend = 0.02, respectively). Excluding 6 years of follow-up reduced this RR (95% CI) for aspartate aminotransferase to 1.22 (1.01-1.49), but even after excluding 10 years follow-up the RR (95% CI) for alanine aminotransferase was unchanged [1.36 (1.01-1.83)]. Although fasting serum glucose has been found previously to be associated with pancreatic cancer risk in this cohort, most other factors that characterize insulin resistance syndrome were not associated with pancreatic cancer risk. The association with elevated liver enzyme levels is a novel finding that warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=39449096885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449096885&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-07-0507

DO - 10.1158/1055-9965.EPI-07-0507

M3 - Article

C2 - 18268120

AN - SCOPUS:39449096885

VL - 17

SP - 359

EP - 364

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -